FIELD: medicine.
SUBSTANCE: invention relates to medicine and relates to a pharmaceutical dosage form for the treatment of a neuropsychiatric disorder. Dosage form contains 800 mg of acamprosate, a calcium salt thereof or other pharmaceutically acceptable salt thereof, and a carbomer of homopolymer type B, which is present in an amount of 5 to 20 % by weight of the dosage form, without any coating.
EFFECT: invention enables to administer to a patient large doses of calcium acamprosate when eating/fasting, while simultaneously avoiding side effects in the gastrointestinal tract.
3 cl, 4 dwg, 13 tbl, 16 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITION FOR TREATING METABOLIC DISORDERS | 2011 |
|
RU2586742C2 |
| COMPOSITIONS CONTAINING BENZOATE COMPOUND AND TANNIC ACID FOR TREATMENT OF DISORDER OF CENTRAL NERVOUS SYSTEM | 2017 |
|
RU2756812C2 |
| NEW COMBINATION COMPRISING N-ACETYL-L-CYSTEINE AND ITS USE | 2012 |
|
RU2605287C2 |
| PREPARATIONS FOR TREATING ADIPOSE TISSUE, SKIN TISSUE AND DISORDERS, AND MUSCULAR TISSUE | 2007 |
|
RU2420317C2 |
| MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | 2011 |
|
RU2560729C2 |
| REGIME OF ADMINISTRATION OF INHIBITORS OF [H,K]-ATPASE | 1997 |
|
RU2203662C2 |
| LAYERED PHARMACEUTICAL COMPOSITIONS | 2007 |
|
RU2452471C2 |
| OCTREOTIDE DELIVERY FROM DRY DOSAGE FORMS | 2009 |
|
RU2518745C2 |
| TREATMENT OF ESSENTIAL TREMOR, USING (R)-2-(4-ISOPROPYLPHENYL)-N-(1-(5-(2,2,2-TRIFLUORETHOXY)PYRIDINE-2-YL)ETHYL)ACETAMIDE | 2019 |
|
RU2780318C1 |
| APPLICATION OF TIZANIDINE AS DRUG-INDUCED PARKINSONISM CORRECTOR | 2008 |
|
RU2393860C2 |
